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We propose in this paper a unified approach for testing the association between rare variants and phenotypes in sequencing association
studies. This approach maximizes power by adaptively using the data to optimally combine the burden test and the nonburden
sequence kernel association test (SKAT). Burden tests are more powerful when most variants in a region are causal and the effects are
in the same direction, whereas SKAT is more powerful when a large fraction of the variants in a region are noncausal or the effects of
causal variants are in different directions. The proposed unified test maintains the power in both scenarios. We show that the unified
test corresponds to the optimal test in an extended family of SKAT tests, which we refer to as SKAT-O. The second goal of this paper
is to develop a small-sample adjustment procedure for the proposed methods for the correction of conservative type I error rates of
SKAT family tests when the trait of interest is dichotomous and the sample size is small. Both small-sample-adjusted SKAT and the
optimal unified test (SKAT-O) are computationally efficient and can easily be applied to genome-wide sequencing association studies.
We evaluate the finite sample performance of the proposed methods using extensive simulation studies and illustrate their application
using the acute-lung-injury exome-sequencing data of the National Heart, Lung, and Blood Institute Exome Sequencing Project.Introduction
Array-based genotyping technologies have been used
successfully in hundreds of genome-wide association
studies in the last few years for identifying over one
thousand common genetic variants associated with many
complex diseases. The recent advance of massively parallel
sequencing technologies1,2 has transformed human
genetic research. These emerging sequencing technologies
provide a richopportunity to study the association between
rare variants and complex traits. Rare variants, which have
minor allele frequencies (MAFs) of less than 0.01~0.05,
might play an important role in the etiology of complex
traits and account for missing heritability unexplained by
common variants.3,4 Several complex traits have been
found to be associated with rare variants.5–7
In recent years, significant efforts have been devoted
to developing powerful and computationally efficient
statistical methods for testing associations between rare
variants and complex traits. Single-variant tests are typi-
cally conducted to investigate associations of common
variants and phenotypes; however the same approach
has little power for testing for rare-variant effects because
of their low frequencies and large numbers. Instead, the
statistical development of rare-variant analysis has been
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be broadly classified as burden and nonburden tests.
Burden tests collapse rare variants in a genetic region
into a single burden variable and then regress the pheno-
type on the burden variable to test for the cumula-
tive effects of rare variants in the region. Examples of
the burden tests include the cohort allelic sum test,8 the
combined multivariate and collapsing method,9 and the
nonparametric weighted sum test (WST),10 which imposes
weights when collapsing rare variants. Several alternative
burden methods are largely based on the same ap-
proach.11–14 Because all burden tests implicitly assume
that all the rare variants in a region are causal and affect
the phenotype in the same direction with similar magni-
tudes, they suffer from a substantial loss of power when
these assumptions are violated.15,16
Kernel-based test methods, such as the sequence kernel
association test (SKAT),17 are nonburden tests. Instead of
aggregating variants, SKAT aggregates individual variant-
score test statistics with weights when SNP effects are
modeled linearly. More generally, SKAT aggregates the
associations between variants and the phenotype through
a kernel matrix and can allow for SNP-SNP interactions,
i.e., epistatic effects. SKAT is especially powerful when
a genetic region has both protective and deleterious vari-
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a variance-component test in the induced mixed models
wherein regression coefficients are assumed to be indepen-
dent and follow a distribution with the variance compo-
nent. SKAT efficiently calculates the p value analytically
for large samples; hence, it is computationally fast for
analyzing genome-wide sequencing association studies.
It has been shown that some nonburden tests15,18,19
constitute a special case of SKAT.16,17
Although SKAT provides attractive power andmakes few
assumptions about rare-variant effects, it has several limi-
tations. It can be less powerful than burden tests if a large
proportion of the rare variants in a region are truly causal
and influence the phenotype in the same direction.16,17
In addition, large-sample-based p value calculations,
which SKAT uses, can produce conservative type I errors
for small-sample case-control sequencing association
studies, which could lead to power loss.17,20 This is partic-
ularly an issue in current exome-sequencing studies, which
are often of small sizes.
This paper aims to address the limitations of burden
tests and SKAT and has two objectives. First, we propose
a unified test for rare-variant effects by using the data to
find the optimal linear combination of the burden test
and SKAT to maximize the power. We show that this
unified test belongs to an extended SKAT family by
allowing the correlation of the regression coefficients of
variants.21 We hence term this optimal unified test, which
is optimal in both scenarios, as SKAT-O. Specifically, using
the data, SKAT-O automatically behaves like the burden
test when the burden test is more powerful than SKAT,
and behaves like SKAT when the SKAT is more powerful
than the burden test.
The second objective of this paper is to improve
the performance of SKAT and SKAT-O in small-sample
case-control sequencing association studies. The original
SKAT test has been found to be conservative for small
samples.17,20 In this paper, we develop an analytic adjust-
ment method for SKATand SKAT-O by precisely estimating
the small-sample variance and kurtosis. This allows us to
precisely calculate the reference distribution for a small
sample, thereby properly controlling the type I error.
This is motivated by the fact that many of the current
exome-sequencing studies, such as those in the National
Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project (ESP), have small sample sizes; e.g.,
the acute lung injury (ALI) exome-sequencing data that
are discussed in this paper have 88 subjects and the chronic
Pseudomonas aeruginosa infection exome-sequencing data
have 91 subjects.22 The proposed small-sample adjustment
method is computationally fast and can be effectively
applied to whole-exome and whole-genome sequencing
studies.
Using extensive simulations and analysis of the ALI
exome-sequencing data of the NHLBI Lung Grand Oppor-
tunity (GO) ESP, we demonstrate that the small-sample-
adjusted unified test (SKAT-O) has proper type I error rates
for small-sample sequencing association studies, hasThe Americhigher power in a wide range of settings, and is more
robust than SKAT and the burden tests.Material and Methods
For simplicity, we assume that we are interested in testing the
association between rare variants in a region, e.g., a gene, and
a complex trait. For whole-exome and whole-genome sequencing
studies, the samemethod can be applied to one gene or one region
at a time and then adjusted for multiple comparisons with the
user’s method of choice. For whole-genome sequencing studies,
one can consider analysis of one window of the same size, e.g.,
10 kb, at a time using themoving-window approach or of different
sizes, using haplotype blocks.
Sequence Kernel Association Test
Assume n subjects are sequenced in a region, e.g., a gene, that
has m variants. For the ith subject, let yi denote a dichotomous
phenotype, Gi ¼ ðgi1;.; gimÞ0 the genotypes of the m variants
ðgij ¼ 0;1;2Þ, and Xi ¼ ðxi1;.; xisÞ0 the covariates. Without loss
of generosity, we assume an additive genetic model and a binary
trait. Results are similar for quantitative traits. To relate genotypes
to a dichotomous phenotype, we consider the logistic regression
model
logitðpiÞ ¼ g0 þX0ig1 þG0ib; (Equation 1)
where pi is the disease probability, g1 is an s31 vector of regression
coefficients of covariates, and b ¼ ðb1;.; bmÞ0 is an m31 vector of
regression coefficients of genetic variants. The standardm degrees
of freedom (df) test for no genetic association, H0: b ¼ 0, has little
statistical power when m is large. Several approaches have been
proposed to reduce the df and increase analysis power. Two classes
of tests have been proposed: burden and nonburden tests.
Burden tests treat the b
0
j s as the same up to a weight function;
i.e., bj ¼ wjbc, where wj is a weight function that may depend on
properties of the jth variant. For example, one can assume wj to
be a function of MAF. Then Equation 1 becomes
logitðpiÞ ¼ g0 þX
0
ig1 þ bc
(Xm
j¼1
wjgij
)
; (Equation 2)
and the association between them genetic variants and a dichoto-
mous trait can be tested using a one-df test for H0: bc ¼ 0. Supposebpi is the estimated probability of yi under the null hypothesis; i.e.,bpi is calculated by fitting the null model
logitðpiÞ ¼ g0 þX0ig1: (Equation 3)
Then the burden score statistic for testing H0 : bc ¼ 0 is
QB ¼
"Xn
i¼1

yi  bpi
 Xm
j¼1
wjgij
!#2
; (Equation 4)
which asymptotically follows scaled c21 under the null hypothesis.
This weighted burden test is equivalent to theWSTof Madsen and
Browning10 and Han and Pan,13 wherein Madsen and Browning10
assumed wj ¼ 1
. ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
~pjð1 ~pjÞ
q
, where ~pj is the estimated MAF for
SNP j using controls. When all wj are the same and analysis is
restricted to rare variants, e.g., the variants with MAF < 5%, QB
is equivalent to the Morris and Zeggini test.12 The key limitation
of the weighted burden test is that it assumes all rare variants inan Journal of Human Genetics 91, 224–237, August 10, 2012 225
the region are causal and are associated with the trait in the same
direction with the same magnitude after weighting, and thus the
presence of both protective and deleterious variants or a large
number of noncausal variants would substantially reduce its statis-
tical power.
SKAT,17 which includes the C-alpha test15 and the SSU test18 as
a special case, is a nonburden test. SKAT assumes that the bj in
Equation 1 are independent and follow an arbitrary distribution
with mean 0 and variance w2j t. The null hypothesis H0 : b ¼ 0 in
the model in Equation 1 is equivalent to the hypothesis
H0 : t ¼ 0. Hence, SKAT is a variance-component test under the
induced logistic mixed model.23 Specifically, under the logistic
model (Equation 1), the SKAT statistic can be written as
QS ¼ ðy bpÞ0Kðy bpÞ; (Equation 5)
where bp ¼ ðbp1;.; bpnÞ0 is a vector of the estimated probability of
y under the null model (Equation 3), and K ¼ GWWG0 is an
n3n kernel matrix, where G ¼ ðG1;.GnÞ0 is an n3m genotype
matrix, and W ¼ diagðw1;.;wmÞ is an m3m diagonal weight
matrix. The SKAT statistic QS can be simplified as the weighted
sum of the individual SNP score statistics as
QS ¼
Xm
j¼1
w2j S
2
j ¼
Xm
j¼1
w2j
(Xn
i¼1
gij

yi  bpi
)2
; (Equation 6)
where Sj ¼
Pn
i¼1gijðyi  bpiÞ is the score statistic for testing
H0 : bj ¼ 0 in the single-SNP model with only the jth SNP,
logitðpiÞ ¼ g0 þX0igþ gijbj:
Note that the notation of the weights wj here is slightly different
from that of Wu et al.17 Our w2j here was denoted as wj in Wu
et al.17Wemodified the notation in this paper to allow for a simple
notation for the burden test.
The weight wj can be flexibly chosen using the observed data,
such as a function of MAF, or external information, such as
a PolyPhen or SIFT score.24,25 For example, the beta density
function of MAF can be used as a weight function in which
wj ¼ Betaðpj; a1; a2Þ, where pj is the estimated MAF for SNP j using
all cases and controls, and the parameters a1 and a2 are prespeci-
fied. The SKAT test statistic QS asymptotically follows a mixture
of chi-square distributions.17 For large samples, the p value of
SKAT can be quickly and accurately calculated by either matching
the moments or inverting the characteristic function.26–28
A comparison of the burden statistic QB in Equation 4 and the
SKAT statistic QS in Equation 6 shows that the burden test aggre-
gates the variants first before performing regression, whereas
SKAT aggregates individual variant-test statistics. Hence, SKAT is
robust to the mixed signs of bs and a large fraction of noncausal
variants.Optimal Unified Association Test
The foregoing discussions suggest that burden tests are not power-
ful when the target region has many noncausal variants or when
causal variants have different directions of association, whereas
SKAT is powerful in these situations.17 However, if the target
region has a high proportion of causal variants with the effects
in the same direction, burden tests can be more powerful than
SKAT. Because such prior biological knowledge is often unknown,
and the underlying genetic mechanisms vary from one gene to
another across the genome, the development of a test that is
optimal for both scenarios in whole-exome and whole-genome226 The American Journal of Human Genetics 91, 224–237, August 1sequencing studies is of substantial interest. Here, we propose
a unified test that includes burden tests and SKAT in one frame-
work. In particular, the test statistic of the proposed unified test is
Qr ¼ rQB þ ð1 rÞQS; 0%r%1; (Equation 7)
which is a weighted average of SKAT and burden-test
statistics. One can easily see that the unified test reduces to
SKAT when r ¼ 0 and to the burden test when r ¼ 1 ; i.e, the
class of tests Qr ð0%r%1Þ includes the burden test and SKAT as
special cases. One can further show that the unified test (Equa-
tion 7) is equivalent to the generalized SKAT test,21 derived as
the variance component score statistic assuming the regression
coefficients bj in Equation 1 follow an arbitrary distribution with
mean 0 and variance w2j t and pairwise correlation r between
different bj s as
Qr ¼ ðy bpÞ0Krðy bpÞ; (Equation 8)
where Kr ¼ GWRrWG0 is an n3n kernel matrix, Rr ¼
ð1 rÞIþ r1 1 0 is an m3m compound symmetric matrix, and
1 ¼ ð1;.1Þ0. This implies that the weight r in Equation 7 can
be interpreted as the correlation of the regression coefficients bj s
ðj ¼ 1;.;mÞ. If the regression coefficients bj are perfectly corre-
lated ðr ¼ 1Þ, they will be all the same after weighting, and one
should collapse the variants first before running regression, i.e.,
using the burden test. If the regression coefficients are unrelated
to each other, one should use SKAT.
In practice, the optimal weight r is unknown and needs to be
estimated from the data to maximize the power. Lee et al.21
proposed the optimal-test procedure for the generalized SKAT,
which selects the weight r to maximize the power. It follows
that the optimal unified test can be calculated as
Qoptimal ¼ min
0%r%1
pr; (Equation 9)
where pr is the p value computed on the basis of a given r. The
optimal-unified-test statistic can be easily obtained through the
simple grid search: set a grid 0 ¼ r1 < r2 <. < rb ¼ 1, then
Qoptimal ¼ min
n
pr1 ;.; prb
o
:
For large samples, Lee et al.21 showed that for a given r, each test
statisticQr can be decomposed into a mixture of two random vari-
ables; one asymptotically follows a chi-square distribution with
one df, and the other can be asymptotically approximated to
a mixture of chi-square distributions with a proper adjustment.
Hence, the p value of Qoptimal can be quickly obtained analytically
with the use of a one-dimensional numerical integration.We term
the optimal unified test as SKAT-O in view of the fact that it is an
optimal test in the generalized SKAT family.Small-Sample Optimal Unified Test
One of the key strengths of SKAT and SKAT-O over the other
competing methods is their ability to efficiently compute asymp-
totic p values without the need for resampling; also, it is easy to
adjust for covariates. This is particularly advantageous in whole-
genome and whole-exome sequencing studies wherein a large
number of tests are performed and one needs to control for
multiple comparisons and account for population stratification.
However, when the trait is binary and sample sizes are small,
e.g., hundreds of subjects, the large-sample-based p value calcula-
tions in Wu et al.17 and Lee et al.21 have been found to produce0, 2012
conservative results, which can lead to incorrect type I error
control and power loss.17,20,21
As most current whole-exome sequencing studies, such as those
of the NHLBI ESP, have small sample sizes, there is a pressing need
to develop a method that works well for small samples. We
propose in this section small-sample-adjusted p value calculations
for SKAT and SKAT-O.
We first consider p value calculations for SKAT when sample
sizes are small. When variants are rare, and the genotype matrix
G is sparse, the small-sample variance of QS is much smaller
than the asymptotic variance. Hence, we readjust the moments
of the null distribution of QS. Suppose QS was obtained with
known p. Denote this with D ¼ diagfpið1 piÞg, where pi is the
probability of being a case under the null. Let ~K ¼ D1=2KD1=2,
L ¼ diagfl1;.; lqg be a diagonalmatrix of ordered nonzero eigen-
values, U ¼ ½u1;.uq be an n3q eigenvector matrix of ~K, and uij
be the ith element of uj. In Appendix A, we show that the small-
sample mean and variance of SKAT under the null hypothesis are
E½QS jU;L;p ¼
Xq
j¼1
lj and Var½QS jU;L;p ¼
Xq
j¼1;k¼1
ljlkcjk;
(Equation 10)
where
cjk ¼
Xn
i¼1
u2iju
2
ik

3p2i  3pi þ 1

pið1 piÞ þ
Xn
i1si2
u2i1 ju
2
i2k
þ 2
Xn
i1si2
ui1 jui2 jui1kui2k  1:
A comparison of these results with those in Wu et al.17 shows
that the small-sample mean of Qs is the same as the asymptotic
mean of QS, but the small-sample variance differs from the asymp-
totic variance.With the use of the estimatedmoments, the p value
can then be calculated as
1 F
 
QS  mQ
 ﬃﬃﬃﬃﬃﬃﬃﬃ
2df
pﬃﬃﬃﬃﬃ
vQ
p þ df jc2df
!
; (Equation 11)
where Fð$jc2df Þ is the distribution function of c2df , and
mQ ¼
Xq
j¼1
lj; vQ ¼
Xq
i;j¼1
liljbcij; and df ¼
 Pq
j¼1
l2j
!2
Pq
j¼1
l4j
;
and lj ¼ ljbcjj= ﬃﬃﬃ2p . bcjk is an estimated cjk with bp. We can apply the
same approach to SKAT-O; details are shown in Appendix B.
Note that the results here do not restrict the kernel matrix K to
be the linear weighted kernel. This proposed small-sample adjust-
ment procedure can be used for all types of kernelmatrices, such as
identity-by-state (IBS) and IBS-weighted kernels17,29Small-Sample SKAT and Unified Test with Higher
Moments Adjustments
In the previous section, we adjusted the asymptotic null distribu-
tion of QS and Qoptimal using the small-sample variance of QS and
Qoptimal. If the sample size is very small, e.g., n ¼ 88 in the ALI
whole-exome sequencing data, this approach may not be accurate
enough to correct small-sample type I error rates. We thus need to
adjust for higher moments, especially kurtosis. Unfortunately,
deriving the analytical formula of the kurtosis of QS is a daunting
task. Hence, we propose a practical approach in which the kurtosis
is estimated through a resampling method. When there is no
covariate, the kurtosis of the null distribution of QS can be esti-The Americmated from B permutation samples of phenotypes, and then the
estimated kurtosis can be used to calculate the df parameter in
Equation 11.
Specifically, suppose Qs;b ðb ¼ 1;.;BÞ is the SKAT test statistic
from the permutation sample yb. The sample kurtosis is
bg ¼ bm4bs4  3;where
bm4 ¼ 1B XB
b¼1

Qs;b  mQ
4
; and bs2 ¼ 1
B
XB
b¼1

Qs;b  mQ
2
:
The df of the mixture of the chi-square distribution ðdf Þ in
Equation 11 is modified as
df ¼ 12bg ;
and the p values can be calculated with Equation 11.
When there are covariates to adjust for, the simple permuta-
tion method cannot be used. Instead, we propose to generate
resampled phenotypes from the parametric bootstrap.30 We first
estimate pi under the null model and use it to generate yb with
the same number of cases and controls.
It should be noted that our method has a computation-time
advantage over calculating p values on the basis of permutations
or bootstrap samples that are obtained as a proportion ofQs;b larger
than QS. For whole-exome sequencing studies, one needs to calcu-
late p values at the 105–106 level to account for multiple
comparison adjustments for performing tests for 20,000 genes.
This requires more than 107–108 permutations or bootstraps for
each gene. However, our approach requires sampling phenotypes
under the null model only 10,000 times to obtain stable estimates
of the higher moments. Note that the null model is the same
across different genes, and hence the same resampled bootstrap
phenotypes under the null model can be used for all the genes
across the genome. Hence, we can save a substantial amount of
computation time.Numerical Simulations
We conducted extensive simulation studies to evaluate the
performance of the proposed methods for binary traits when
sample sizes are small. We generated sequence data of European
ancestry from 10,000 chromosomes over 1 Mb regions using the
calibrated coalescent model.31 We randomly selected regions
with lengths of 3 kb and tested for associations in all simulation
settings.
Type I Error Simulations
We first generated data sets under the null model to evaluate
the type I error control of the proposed methods. Dichotomous
phenotypes with 50% cases and 50% controls were generated
from the null logistic regression model
logitðpiÞ ¼ g0 þ 0:5X1i þ 0:5X2i;
whereX1 was a continuous covariate fromNð0;1Þ, X2 was a binary
covariate from Bernoullið0:5Þ, and g0 was chosen to create a trait
prevalence of 0.01 under the null hypothesis. We applied six
different methods to each of the randomly selected 3 kb regions:
(1) counting-based burden test (N); (2) weighted burden test
(W); (3) SKATwithout small-sample adjustment (SKAT); (4) unified
test without small-sample adjustment (SKAT-O); (5) small-sample-
adjusted SKAT (adjusted SKAT); and (6) small-sample-adjusted
unified test (adjusted SKAT-O).an Journal of Human Genetics 91, 224–237, August 10, 2012 227
Table 1. Simulation Studies of Type I Error Estimates of Four
Different Methods of Testing an Association between Randomly
Selected 3 kb Regions with Dichotomous Traits at Stringent
a Levels a ¼ 103, 104, and 2.53106.
a SKAT SKAT-O
Adjusted
SKAT
Adjusted
SKAT-O
Sample Size ¼ 200
103 1.84 3 104 5.03 3 104 1.13 3 103 1.24 3 103
104 5.30 3 106 3.20 3 105 1.01 3 104 1.04 3 104
2.5 3 106 1.00 3 107 3.00 3 107 3.20 3 106 2.50 3 106
Sample Size ¼ 500
103 5.17 3 104 8.14 3 104 1.12 3 103 1.16 3 103
104 2.95 3 105 7.13 3 105 1.14 3 104 1.12 3 104
2.5 3 106 1.00 3 107 1.00 3 106 2.50 3 106 2.30 3 106
Sample Size ¼ 1,000
103 7.22 3 104 1.00 3 103 1.09 3 103 1.12 3 103
104 5.59 3 105 1.02 3 104 1.22 3 104 1.19 3 104
2.5 3 106 1.00 3 106 2.80 3 106 3.20 3 106 3.10 3 106
Each entry represents type I error rate estimates as the proportion of p values
smaller than a under the null hypothesis based on 107 simulated phenotypes.For all methods except N, Betað1;25Þ weights were used to
upweight rarer variants. For N, we used flat weights and restricted
variants with observed MAF < 0:03. For both N and W, the
likelihood-ratio test was used to compute p values. The p values
of the optimal unified tests were computed using the 11 points
of equal-sized grids search of r from 0 to 1. For adjusted SKAT
and adjusted SKAT-O, the sample kurtosis was estimated from
10,000 bootstrapped phenotype sets. Three different total sample
sizes (n¼ 200, 500, and 1,000) were considered, with 10,000 simu-
lated data sets for each sample size.
To investigate type I error rates in the SKAT family tests when
the a level is set at a level for exome-wide testing, we conducted
simulations with slightly different settings. In order to reduce
the computational burden, we first generated 20,000 genotype
sets of randomly selected regions, and we then generated 500
phenotype sets for each genotype set. A total of 107 phenotypes
were generated, and type I error rates were estimated by the
proportion of p values smaller than the given a level.
Power Simulations
To evaluate the power of the proposed unified tests and their
small-sample adjustments relative to the competing methods,
we simulated data sets under the alternative model. As with the
type I error simulations, we randomly selected 3 kb regions from
a broader 1 Mb region, but we then randomly chose causal
variants from the rare variants with true MAF < 0:03. The dichot-
omous phenotypes with 50% cases and 50% controls were simu-
lated from
logitðpiÞ ¼ g0 þ 0:5Xi1 þ 0:5Xi2 þ b1gi1 þ/þ bsgis;
where ðg1;/; gsÞ were selected causal variants. Covariates X1 and
X2 followed the same distribution as in the type I error simulation,
and g0 was chosen to set the disease prevalence as 0.01 under the
null hypothesis.
To study the effects of varying proportions of variants being
causal variants, we considered three different settings, in which
10%, 20%, and 50% of the rare variants were causal variants. For
each setting, we considered three different sign configurations of
the nonzero bs: all bj s were positive, 80% of bj s were positive,
and 50% of bj s were positive. We used
bj ¼ cjlog10ðpjÞj=2, where
pj was the MAF of the j
th variant. When 10% of the rare variants
were causal, c ¼ logð7Þ, which gives an odds ratio equal to 7 for
a variant with MAF ¼ 0.01. When 20% and 50% of the rare vari-
ants were causal variants, c ¼ logð5Þ and logð2:5Þ, respectively;
therefore, the powers would not be too close to 1, and we can
distinguish the powers of different methods. For each setting,
1,000 data sets were generated, and the power was estimated as
the proportion of p values smaller than a given a level.The NHLBI ALI Exome-Sequencing Data
The ALI whole-exome sequencing data were part of the Lung GO
of the NLBLI ESP. We performed exome sequencing of 88 in-
dividuals with ALI32 selected from the extremes of the severity
spectrum. Individuals with ALI and severe hypoxemia (ratio of
partial pressure of arterial oxygen to fraction of inspired oxygen
< 200) were enrolled from the intensive care unit at theMassachu-
setts General Hospital. Those with very high or very low ‘‘venti-
lator-free days’’ (VFD), a composite variable measuring the degree
of dependence on mechanical ventilation in the first 28 days
of hospital admission,33 were selected for sequencing. Exome
sequencing was completed on 88 subjects (n ¼ 43 high severity
ALI [VFD < 2], n ¼ 45 low severity ALI [VFD < 24]) at the North-228 The American Journal of Human Genetics 91, 224–237, August 1west Genomics Center at the University of Washington. This
study was approved by the institutional review boards of the
Massachusetts General Hospital, the Harvard School of Public
Health, and the University of Washington.
The Genome Analysis Toolkit (GATK) of the Broad Institute was
used for calling SNP variants,34 and approximately 130,000 SNP
variants on 17,755 genes were identified. We subsequently filtered
out variants with high missing rates (missing rate > 0:1) and low
quality-control scores using GATK, i.e, keeping variants with
Qual < 30, QD < 5, AB > 0.75 or SB > 0.10, and % of
missing < 10 %. This yielded a total of 106,736 variants.
For SKAT and the unified test (SKAT-O), we used all the variants.
For the weighted burden test (W) and the counting-based burden
test (N), because of the very small sample size, we usedMAF< 0.05
as the criterion for defining rare variants to be included in the
analysis. Any genes with fewer than four rare variants with
MAF < 0.05 were excluded from the analysis, as these genes
have little information about association with the phenotype
given the small sample size. A total of 6,488 genes remained for
analysis. All six methods discussed in the simulation study were
applied to the data. The first two principal components calculated
with EIGENSOFT35 from all 106,736 variants were used as covari-
ates for adjustment of possible population stratification.Results
Type I Error Simulation Results
To investigate the type I error rates with exome-wide
a levels, we generated 107 data sets. The results are given
in Table 1. Three different a ¼ 103; 104, and 2:53106
levels were considered. Note that a ¼ 2:53106 is Bonfer-
roni-adjusted level a ¼ 0:05 when simultaneously testing
20,000 genes. Table 1 clearly shows that the unadjusted
SKAT and unified test (SKAT-O) had substantially deflated0, 2012
type I error rates for small sample sizes. The unified test
(SKAT-O) was less conservative than SKAT and had correct
type I error control when the sample size was 1,000. Both
the proposed small-sample-adjusted SKAT and the unified
test (adjusted SKAT and adjusted SKAT-O) performed
much better than their unadjusted counterparts in small
samples. They controlled type I error rates accurately
over all sample sizes and all significance levels. We also
evaluated the type I error rates of the burden tests and
SKAT and SKAT-O tests at a ¼ 0:05 using 10,000 simulated
data sets (Table S1 available online), and the results agreed
with Table 1. Overall, our type I error simulation results
confirm empirically that the proposed small-sample
adjustment methods accurately control type I error rates.
Power Simulation Results
We compared the powers for the burden tests, SKAT, and
the unified test (SKAT-O) and their small-sample adjust-
ments, i.e., all of the six methods considered in the
type I error simulations. The number of observed variants
is given in Table S2. On average, depending on sample
sizes, 20 to 40 variants were observed in each region. We
first considered the scenario that all causal variants were
deleterious variants, i.e., that the effects of the causal
variants were all in the same direction. Figure 1 reports
that by properly controlling the type I error, the small-
sample-adjusted SKAT (adjusted SKAT) was more powerful
than SKAT in every configuration, and the power gap was
large when the sample size was small or when the signi-
ficance level was small. The power for SKAT-O and its
small-sample adjustment (adjusted SKAT-O) showed a
similar pattern. Between the two burden tests, W was
more powerful than N for these simulation configurations,
suggesting that proper weighting can increase power.
When only 10% of the rare variants were causal,
adjusted SKATwas themost powerful test. The burden tests
had the substantially lowest power, indicating that burden
tests are not powerful in the presence of a large fraction of
noncausal variants. When the proportion of causal rare
variants increased, the burden tests performed better.
When 50% of the rare variants were causal, the burden
tests had a higher power than adjusted SKAT.
The optimal unified tests (SKAT-O and adjusted SKAT-O)
consistently performed very well in both settings above.
They behaved like SKAT when SKAT was more powerful
than the burden tests, and they behaved like burden tests
when the burden tests were more powerful than SKAT.
Adjusted SKAT-O outperformed its unadjusted counterpart
(SKAT-O), especially when sample sizes were small, e.g.,
n ¼ 200. When 20% of rare variants were causal, adjusted
SKAT-O was the most powerful test.
We next performed simulations in which 20%/80% and
50%/50% of causal variants were protective/deleterious
variants (Figures 2 and 3). The same odds-ratio functions
from above were used. Similar to the case wherein all
causal variants were deleterious (Figure 1), adjusted SKAT
had higher power than SKAT, and adjusted SKAT-O hadThe Americhigher power than its unadjusted counterpart (SKAT-O).
The presence of mixed protective and deleterious variants
substantially reduced the powers of burden tests, because
the effects of the causal variants canceled out. With 50%/
50% of the causal variants being protective/deleterious,
the powers of the burden tests were less than half those
of SKAT and its small-sample adjustment. The optimal
unified test behaved similarly to SKAT but had better
power than SKAT and the burden test when 50% of the
rare variants were causal and 50%/50% of the causal vari-
ants were protective/deleterious. Small-sample adjustment
for both SKAT and the unified test improved the power. All
tests had lower power relative to the situation in which all
causal variants were deleterious (Figure 1). This is because
for the given low prevalence, the presence of protective
variants resulted in fewer causal variants selected into the
case-control sample (Table S3).
We present the optimal r values estimated by adjusted
SKAT-O in Figure S5. It shows that SKAT-O generally
selects large r values when the percentage of causal vari-
ants is high and all causal variants are deleterious, and
selects small rs when either the percentage of causal vari-
ants is low or some causal variants are protective. The
estimated optimal r varies between different data sets as
it accounts for sampling variation. We also conducted
additional simulations for the extreme situation in which
all rare variants in a region were causal and deleterious
(Figure S6). In this scenario, the theoretical optimal
r ¼ 1. As expected, W has the highest power. The adjusted
SKAT-O has a slightly smaller power than W, because it
assumes r is unknown and searches for the optimal r in
[0,1]. However, the power gap between W and adjusted
SKAT-O is small.
The power simulation results show that the optimal
unified test (SKAT-O) is robust to the proportion of rare
variants that are causal and to the directions of the causal
variant effects (relative to the other tests), it performs very
well in a wide range of situations, and it outperforms SKAT
and the burden tests. The proposed small-sample adjust-
ment increases the power by properly controlling for
type I error rate, especially when the sample size is small
or a is very small.
Analysis of the NHLBI ALI Exome-Sequencing Data
We applied the six methods used in the simulation studies
(burden tests, SKAT, the unified test [SKAT-O], and their
small-sample adjustments) to analysis of the NHLBI ALI
exome-sequencing data of 88 subjects to identify genes
associated with ALI severity. We restricted our analysis
to the genes with at least four variants with MAFs < 0.05.
A total of 6,488 genes were analyzed (see Material and
Methods).
Figure 4 gives the quantile-quantile (Q-Q) plots of the
pvalues calculatedwith theuseof all the sixmethods.Given
the small sample size, no p value achieved the Bonferroni-
adjusted genome-wide significance of a ¼ 7:73106. The
Q-Q plots of the unadjusted SKAT and unified testan Journal of Human Genetics 91, 224–237, August 10, 2012 229
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 10 %
Total Sample Size
Po
w
er
N
W
SKAT
SKAT−O
adjSKAT
adjSKAT−O
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 20 %
Total Sample Size
Po
w
er
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 50 %
Total Sample Size
Po
w
er
α = 0.01
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 10 %
Total Sample Size
Po
w
er
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 20 %
Total Sample Size
Po
w
er
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 50 %
Total Sample Size
Po
w
er
α = 10−3
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 10 %
Total Sample Size
Po
w
er
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 20 %
Total Sample Size
Po
w
er
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 50 %
Total Sample Size
Po
w
er
α = 2.5x10−6
Figure 1. Power Estimates for the Six Competing Methods when All Causal Variants Were Deleterious
Empirical power of the six methods for randomly selected 3 kb regions wherein all causal variants were deleterious. From top to bottom,
the plots consider the significance levels 0.01, 103, and 2:53106, respectively. From left to right, the plots consider settings in which
10% of rare variants were causal, 20% of rare variants were causal, and 50% of rare variants were causal, respectively. For causal variants,
we assumed
bj ¼ cjlog10ðpjÞj=2, where pj was the MAF of the jth variant. A different c was used for the three panels from left to right:
c ¼ logð7Þ; logð5Þ; logð2:5Þ for the percentage of causal variants being 10%, 20%, and 50% respectively. Hence, the powers between
the three panels from left to right are not comparable. Total sample sizes considered were 200, 500, and 1,000, and half were cases in
case-control studies.
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Figure 2. Power Estimates for the Six Competing Methods when 20%/80% of Causal Variants Were Protective/Deleterious
Empirical power of the six methods for randomly selected 3 kb regions wherein 20%/80% of causal variants were protective/deleterious.
From top to bottom, the plots consider the significance levels 0.01, 103, and 2:53106, respectively. From left to right, the plots
consider settings in which 10% of rare variants were causal, 20% of rare variants were causal, and 50%of rare variants were causal, respec-
tively. For causal variants, we assumed
bj ¼ cjlog10ðpjÞj=2, where pj was the MAF of the jth variant. A different c was used for the three
panels from the left to the right: c ¼ logð7Þ; logð5Þ; logð2:5Þ for the percentage of causal variants being 10%, 20%, and 50% respectively.
Hence, the powers between the three panels from left to right are not comparable. Total sample sizes considered were 200, 500, and
1,000, and half were cases in case-control studies.
The American Journal of Human Genetics 91, 224–237, August 10, 2012 231
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 10 %
Total Sample Size
Po
w
er
N
W
SKAT
SKAT−O
adjSKAT
adjSKAT−O
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 20 %
Total Sample Size
Po
w
er
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 50 %
Total Sample Size
Po
w
er
α = 0.01
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 10 %
Total Sample Size
Po
w
er
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 20 %
Total Sample Size
Po
w
er
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 50 %
Total Sample Size
Po
w
er
α = 10−3
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 10 %
Total Sample Size
Po
w
er
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 20 %
Total Sample Size
Po
w
er
200 500 10000
.0
0.
2
0.
4
0.
6
0.
8
1.
0
Causal = 50 %
Total Sample Size
Po
w
er
α = 2.5x10−6
Figure 3. Power Estimates for the Six Competing Methods when 50%/50% of Causal Variants Were Protective/Deleterious
Empirical power of the six methods for randomly selected 3 kb regions wherein 50%/50% of causal variants were protective/deleterious.
From top to bottom, the plots consider the significance levels 0.01, 103, and 2:53106, respectively. From left to right, the plots
consider settings in which 10% of rare variants were causal, 20% of rare variants were causal, and 50%of rare variants were causal, respec-
tively. For causal variants, we assumed
bj ¼ cjlog10ðpjÞj=2, where pj was the MAF of the jth variant. A different c was used for the three
panels from left to right: c ¼ logð7Þ; logð5Þ; logð2:5Þ for the percentage of causal variants being 10%, 20%, and 50%. Hence, the powers
between the three panels from left to right are not comparable. Total sample sizes considered were 200, 500, and 1,000, and half were
cases in case-control studies.
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Figure 4. Analysis of the ALI Exome-
Sequence Data
log10 Q-Q plots of observed versus ex-
pected p values for the ALI exome-
sequence data for the six methods: burden
tests (N and W), SKAT, SKAT-O, adjusted
SKAT, and adjusted SKAT-O. The x axis
represents log10 expected p values, and
the y axis represents log10 observed
p values. A total of 6,488 genes with at
least four rare variants were tested for asso-
ciations with ALI severity.(SKAT-O) were skewed downward, suggesting these tests
were conservative. Interestingly, the Q-Q plots of the
burden tests had a slightly anticonservative pattern. The
Q-Q plots of the small-sample-adjusted SKAT and unified
test (adjusted SKAT-O) were close to the 45 degree line,
suggesting that the proposed small-sample adjustment
methods worked well and properly controlled type I error
rates. There were eight genes with p values < 103 by the
adjusted SKAT-O. A total of 741 genes had the estimated
optimal r values between 0.1 and 0.9.
We next restricted our analysis to the functional
variants that are missense, nonsense, and splicing sites.
Similar to the first analysis, we only considered genes that
have at least four functional variants with MAF < 0.05.The American Journal of Human GeA total of 2,939 genes were used in
the analysis. The Q-Q plots of the six
methods are given in Figure S1. The
patterns of these Q-Q plots are similar
to those in Figure 4. There were five
genes with p values < 103 by the
adjusted SKAT-O. Myosin light chain
kinase (MYLK [MIM 600922]), a
gene that was previously found to
be associated with susceptibility to
ALI,36,37 was the second-most signifi-
cant in the adjusted SKAT analysis
and the fourth-most significant in
the adjusted SKAT-O analysis.
We compared the p values ob-
tained using small-sample-adjusted
SKAT (adjusted SKAT) and the adjusted
optimal unified test (adjusted SKAT-O)
with those obtained using the burden
test (W) (Figure S2). These compari-
sons show that the p values obtained
with adjusted SKAT and W are quite
different from each other, indicating
that these two tests evaluate dif-
ferent aspects of association patterns.
In contrast, the p values obtained
with adjusted SKAT-O were more
highly correlated with those obtained
with either adjusted SKAT or W as
p values declined, consistent withthe expectation that the optimal unified test uses the data
to adaptively choose an optimal test to maximize power.
Discussion
In this paper, we present a unified rare-variant test frame-
work that includes both burden tests and the nonburden
SKAT as special cases. The proposed optimal unified test
(SKAT-O) procedure uses the data to adaptively select the
best linear combination of the burden test and SKAT to
maximize test power. Similar to SKAT, the proposed
SKAT-O is computationally efficient and easily adjusts for
covariates such as age, gender, and principal components
for population stratifications. We show in simulationnetics 91, 224–237, August 10, 2012 233
studies that SKAT and burden tests can both lose power
when underlying assumptions are violated. However, the
optimal unified test SKAT-O is more robust in a wide range
of the circumstances we have considered. In the SKAT
package, we also provide power and sample-size calcula-
tions using SKAT, SKAT-O, and their small-sample adjust-
ments to help investigators design sequencing-association
studies.
In whole-exome or whole-genome sequencing studies,
one would expect that some genes or genomic regions
have a high proportion of causal variants with the same
association direction and that other regions have many
noncausal variants or causal variants with different associ-
ation directions. Applying only either a burden test or
SKAT would decrease the chance of detecting all of those
genes. However, the use of SKAT-O is more robust and
will increase the chance of detecting these genes.
Although we have considered in this paper a wide range
of simulation settings that are of practical interest, we note
that simulation results depend on simulation settings.
Thus, our results from comparing different methods
should be interpreted within the context of the range of
simulation settings we have considered. It would be useful
to examine the generality of the results in other simulation
settings in the future.
Due to high sequencing costs, many of the existing
whole-exome sequencing studies have small sample sizes.
As the second goal of this paper, we developed small-
sample adjustment methods to correct p values for SKAT
and SKAT-O to properly control the type I error rate and
increase the power. Using extensive simulation studies
and the NHLBI whole exomes from individuals who devel-
oped ALI, we demonstrated good performance of the
proposed small-sample adjustment methods, both in
terms of type I error control and power increase.
In this study, we only considered dichotomous traits.
However, the application of SKAT-O to quantitative-trait
data is straightforward using Equation 1 with a linear
regression. Furthermore, we note that the small-sample
adjustment is not necessary for continuous traits when
the normality assumption is true, because the small-
sample distributions of SKAT and SKAT-O are the same as
their asymptotic distributions under normality.
We note that the proposed small-sample adjustment
methods are still computationally efficient even though
we estimate the kurtosis using resampling. It only requires
10,000 bootstrap samples to accurately estimate the
kurtosis, which is a substantially smaller computational
burden compared to obtaining permutation or bootstrap
p values, which require 107 or 108 resampled phenotypes
to accurately obtain p values in the 105–106 ranges.
In simulation and real-data analysis, we used a flexible
beta weight to upweight the influence of rarer variants.
Similar results are obtained with the use of logistic weight
wj ¼ expðða1  pjÞa2Þ=f1þ expðða1  pjÞa2Þg for the ALI
exome-sequencing data (see Figures S3 and S4). In addition
to the use of a function of the MAF of variants as weights,234 The American Journal of Human Genetics 91, 224–237, August 1functional information can also be used for choosing
variants to be tested or for constructing the weight. For
example, only functional variants such as nonsense and
missense variants can be used to test association, or func-
tional information scores such as PolyPhen or SIFT
scores24,25 can be used to construct a weight (an area under
active study).
Recently, several adaptive methods have been proposed
to increase the power. For example, the VT test11 tries to
find the optimal MAF threshold of rare variants by varying
the threshold, and EREC20 estimates a regression coeffi-
cient of each variant and uses them as the weight. Those
approaches could improve the power compared to the
burden tests. However, the VT test makes similar assump-
tions to those of the burden tests; i.e, it requires a majority
of rare variants under the optimal threshold to be causal
and have effects in the same direction. The EREC method
requires estimation of regression coefficients, which are
difficult to estimate stably for rare variants. Addition of a
stabilizing constant in EREC can reduce the power rela-
tive to asymptotic calculations and make the test behave
more like burden tests. Furthermore, these methods are
computationally intensive when applied to large-scale
sequencing studies, e.g., whole-exome and whole-genome
sequencing studies, because they rely on a large number of
permutation or bootstrap samples to compute p values and
are difficult to control for covariates, such as population
stratification. In contrast, SKAT-O and its small-sample
adjustment compute p values efficiently and can be easily
applied to whole-exome and whole-genome sequencing
studies.
With the rapid advance of biotechonology, new biolog-
ical knowledge will become available, and new sequencing
technology and study designs will be developed. In the
fast-moving next-generation-sequencing era, it is of signif-
icant importance to incorporate this new information to
improve statistical and computational tools for detecting
rare variants associated with complex diseases.Appendix A. Mean and Variance of QS under the
Null Hypothesis
Suppose ~y ¼ D1=2ðy pÞ, where D ¼ diag½p1ð1 p1Þ;
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where ~yi is the i
th element of ~y, and uij is the ith element
of uj. Therefore,0, 2012
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Because Eð~yi
pÞ ¼ 0, the elements in the second term
in Equation A.2 can contribute to the overall sum only
when (1) i1 ¼ i2 ¼ l1 ¼ l2, (2) i1 ¼ i2 and l1 ¼ l2, (3)
i1 ¼ l1, and (4) i2 ¼ l2 or i1 ¼ l2 and i2 ¼ l1. Therefore
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We can calculate the second moment of QS by com-
bining Equations A.2 and A.3.Appendix B. Null Distribution of Small-Sample
SKAT-O
Define Z ¼ D1=2GW and z ¼ ðz1;.; znÞ0, where zi ¼Pm
j¼1zij=m. Additionally, we let M ¼ zðz0zÞ1z0 and
jðrÞ ¼ m2rz0zþ 1 r
z0z
Xm
j¼1

z0z:j
2
;
where z:j is the jth column of Z. Following the same argu-
ment in Lee et al.,21 it can be shown thatQr is equivalent asThe Americð1 rÞk1 þ jðrÞk2; (Equation A.4)
wherek1 ¼ ð1 rÞ~y0ðIMÞZZ0ðIMÞ~y
þ 2ð1 rÞ~y0ðIMÞZZ0M~y
and
k2 ¼
~y0zz0~y
z0z
:
It can be shown that k2 asymptotically follows the c
2
1
distribution, and k1 is asymptotically the same as
Xq
k¼1
lkhk þ z;
where fl1;.lqg are nonzero eigenvalues of Z0ðIMÞZ,
hkðk ¼ 1;.; qÞ are independent and identically distributed
c21 randomvariables, and z satisfies the following conditions:
EðzÞ ¼ 0; VarðzÞ ¼ 4traceðZ0MZZ0ðIMÞZÞ;
Corr
Pq
k¼1
lkhk; z
	
¼ 0; and Corrðk2; zÞ ¼ 0:
We note that asymptotic p values can be obtained
through the one-dimensional integration. When the
sample size is small, however, the asymptotic moments
of k1 and k2 can be larger than small-sample moments.
Thus, we apply the same small-sample adjustment proce-
dure to null distributions of k1 and k2. We first compute
the small-sample variance and kurtosis of k1 and k2 and
apply the moment-matching approximation to obtain
their adjusted asymptotic distribution. To obtain a p value,
we apply the algorithm in Lee et al.21 with the adjusted
null distribution k1 and k2.Supplemental Data
Supplemental Data include six figures and three tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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Web Resources
The URLs for data presented herein are as follows:
Implementation of SKAT and SKAT-O and their Small-Sample
Adjustments and Power/Sample-Size Calculations in the
R Language, http://www.hsph.harvard.edu/~xlin/software.html
NHLBI Exome Project, http://www.nhlbi.nih.gov/resources/
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